Uwm Research Foundation, Inc.

Centre for Addiction and Mental Health

University of Belgrade—faculty of Pharmacy

Michael Ming-Jin Poe

James M Cook

Guanguan Li

Etienne Sibille

Miroslav M Savic

Ojas A Namjoshi

Hiteshkumar D Jain

Yun Teng Johnson

Jie Yang

Sundari K Rallipalli

Zhi-jian Wang

Terry S Clayton

Kashi Reddy Methuku

James Cook

Provided herein are alpha5-containing GABAreceptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.

Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing GABAreceptor agonists

Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAreceptor agonists

Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with ALPHA5-containing GABAA receptor agonists

Described herein are &#x3b1;3 or &#x3b1;2 or &#x3b1;2/&#x3b1;3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as &#x3b1;3 or &#x3b1;2 or &#x3b1;2/&#x3b1;3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.

Gabaergic ligands and their uses

GABAergic receptor subtype selective ligands and their uses

Gabaergic receptor subtype selective ligands and their uses

Growing community of inventors

Vernon, CT, United States of America

Michael Ming-Jin Poe